Mesothelioma Clinical Trial 205: A Comprehensive Overview

🧬 What is Mesothelioma Clinical Trial 205?

Mesothelioma Clinical Trial 205 is an ongoing clinical trial for patients diagnosed with pleural mesothelioma. The trial is conducted by the National Cancer Institute (NCI) and aims to evaluate the effectiveness of a new treatment regimen for this aggressive cancer.

The trial is open to patients who have not received any prior treatment for their mesothelioma and have not undergone any radiation therapy. Patients who have undergone a surgical procedure to remove their mesothelioma tumor may also be eligible to participate.

📜 Mesothelioma Clinical Trial 205: Complete Information Table

Study ID	Phase	Status	Location	Condition
NCT03026517	Phase 2	Recruiting	Multiple Locations	Pleural Mesothelioma

🏥 How Does Mesothelioma Clinical Trial 205 Work?

The treatment regimen being evaluated in Mesothelioma Clinical Trial 205 combines two medications: pembrolizumab and defactinib. Pembrolizumab is a checkpoint inhibitor that helps the immune system recognize and attack cancer cells. Defactinib is a cancer stem cell inhibitor that targets the stem cells responsible for driving tumor growth and recurrence.

The trial is designed to evaluate the effectiveness of this combination therapy in slowing or stopping the progression of mesothelioma. Participants will receive both medications intravenously once every three weeks until disease progression or unacceptable toxicity occurs.

🧪 Who Can Participate in Mesothelioma Clinical Trial 205?

Mesothelioma Clinical Trial 205 is open to patients who meet the following criteria:

• Diagnosis of pleural mesothelioma
• No prior treatment for mesothelioma
• No prior radiation therapy
• Potentially operable disease
• Adequate organ function
• Agree to use effective contraception during the study period

Patients who have undergone a surgical procedure to remove their mesothelioma tumor may also be eligible to participate.

🔬 What Are the Potential Benefits of Mesothelioma Clinical Trial 205?

Mesothelioma is an aggressive cancer with limited treatment options. Clinical trials such as Mesothelioma Clinical Trial 205 offer patients access to new and promising treatments that may improve their outcomes.

By participating in the trial, patients may benefit from:

• A new treatment option for their cancer
• Care from a team of experienced mesothelioma specialists
• Close monitoring of their disease progression and treatment response

🌡️ What Are the Risks of Mesothelioma Clinical Trial 205?

As with any clinical trial, there are potential risks associated with participating in Mesothelioma Clinical Trial 205. These risks include:

• Side effects of the medications being evaluated
• Complications from the intravenous administration of the medications
• Disease progression or recurrence
• Unintended harm to other organs or systems

Patients will be closely monitored for any adverse effects throughout the trial, and treatment may be discontinued if the risks outweigh the potential benefits.

❓ Frequently Asked Questions About Mesothelioma Clinical Trial 205

1. What is the purpose of Mesothelioma Clinical Trial 205?

The purpose of Mesothelioma Clinical Trial 205 is to evaluate the effectiveness of a new treatment regimen for pleural mesothelioma.

2. Who is eligible to participate in the trial?

Patients who have been diagnosed with pleural mesothelioma, have not received prior treatment or radiation therapy, and have potentially operable disease may be eligible to participate.

3. What is the treatment regimen being evaluated in the trial?

The trial is evaluating a combination therapy of pembrolizumab and defactinib.

4. How long does the treatment last?

Participants will receive the medications once every three weeks until disease progression or unacceptable toxicity occurs.

5. What are the potential benefits of participating in the trial?

Patients may benefit from a new treatment option for their cancer, care from experienced mesothelioma specialists, and close monitoring of their disease progression and treatment response.

6. What are the potential risks of participating in the trial?

The potential risks include side effects of the medications being evaluated, complications from intravenous administration, disease progression or recurrence, and unintended harm to other organs or systems.

7. Can participants receive other treatments while participating in the trial?

Participants cannot receive any other anti-cancer treatments while enrolled in the trial.

8. How is the trial funded?

The trial is funded by the National Cancer Institute.

9. Where is the trial being conducted?

The trial is being conducted at multiple locations.

10. How is the trial being monitored for safety?

The trial is being closely monitored by an independent data and safety monitoring board.

11. How long will the trial last?

The trial is ongoing, and the estimated completion date is December 2022.

12. Will participants receive the treatment for free?

The cost of the medications used in the trial may be covered by the trial sponsor, but participants may be responsible for other medical costs associated with their care.

13. How can interested patients learn more about Mesothelioma Clinical Trial 205?

Patients can speak with their healthcare provider or visit the ClinicalTrials.gov website to learn more about the trial.

📣 Conclusion: Take Action Today

Participating in a clinical trial such as Mesothelioma Clinical Trial 205 offers patients access to promising new treatments that may improve their outcomes. If you or a loved one has been diagnosed with pleural mesothelioma, talk to your healthcare provider about whether participating in this trial is right for you.

Remember, clinical trials are critical for advancing cancer research and developing new therapies for patients in need. By participating in a trial, you can contribute to the fight against cancer and help pave the way for future treatments.

⚠️ Closing/Disclaimer

This article is provided for informational purposes only and is not intended as medical advice. Patients should consult with their healthcare provider regarding their individual treatment options.

The information regarding Mesothelioma Clinical Trial 205 has been obtained from publicly available sources, and the accuracy of this information cannot be guaranteed. Patients should speak with their healthcare provider or visit the ClinicalTrials.gov website for the most up-to-date and accurate information about the trial.